DataMEDS AI Terminates Second Amended and Restated Letter of Intent
DataMEDS AI said it terminated its Second Amended and Restated letter of intent because of market conditions, ending plans to issue shares in connection with the agreement.
DataMEDS AI, Inc. (NASDAQ:MEDS) has ended its Second Amended and Restated letter of intent dated October 19, 2026, citing market conditions. The agreement concerned potential intellectual property licensing or acquisitions in exchange for DataMEDS common stock.
The terminated 2nd LOI involved Datavault AI Inc. (NASDAQ:DVLT), REBOOT Health AI, Inc., a wholly owned subsidiary of Data Health Partners, Inc., EOS Technology Holdings, Inc., Scilex Holding Company and HealthBridge Advisors, LLC.
DataMEDS said it does not owe fees or other obligations as a result of ending the LOI. The company also confirmed that it will not issue shares connected with the terminated agreement.
DataMEDS said its exclusive licence with REBOOT covering the management of GLP-1 users remains in full force and effect under the agreement dated October 13, 2026.
The company also said its agreement with Datavault AI concerning PharmacyChain manufacturer-to-patient blockchain-enabled smart contracts remains in force under the terms dated November 24, 2025. DataMEDS stated that no shares were issued to Datavault AI under that agreement.
DataMEDS describes itself as a healthcare company focused on integrating technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through health information technology platforms. The company incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into Tollo Health's Health Lives Here mobile application.
Its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a commercial clinical molecular diagnostics laboratory based in Pittsburgh, Pennsylvania. Helomics focuses on the ChemoFx Assay chemotherapy selection diagnostics test, which the company says aims to assist oncologists with chemotherapy treatment decisions.
DataMEDS cautioned that statements concerning the effect of the LOI cancellation, potential alternative acquisitions, licences or partnerships, possible costs or disputes, the status of other agreements, future securities issuances, business-plan execution, Nasdaq listing compliance, liquidity, capital resources and funding for operations are forward-looking statements.
The company said actual results may differ materially from those statements because of risks and uncertainties. It also said the statements speak only as of November 3, 2026, and that it has no obligation to update or revise them except as required by law.
DataMEDS announced that it had terminated the Second Amended and Restated letter of intent dated October 19, 2026 with Datavault AI Inc., REBOOT Health AI, EOS Technology Holdings, Scilex Holding Company and HealthBridge Advisors. The company said the termination was due to market conditions.
The 2nd LOI covered the proposed in-licensing or acquisition of intellectual property in exchange for DataMEDS common stock. The parties named in the announcement were Datavault AI Inc. (NASDAQ:DVLT), REBOOT Health AI, EOS Technology Holdings, Scilex Holding Company and HealthBridge Advisors.
DataMEDS said it terminated the 2nd LOI due to market conditions. The announcement does not provide further detail on those conditions.
DataMEDS said it does not owe any fees or obligation as a result of terminating the 2nd LOI.
DataMEDS said it will no longer issue any shares related to the 2nd LOI. The announcement separately states that no shares were issued to Datavault AI in connection with the agreement dated November 24, 2025.
DataMEDS said its exclusive licence with REBOOT for the management of GLP-1 users, dated October 13, 2026, remains in full force and effect. It also said the Datavault AI agreement for PharmacyChain manufacturer-to-patient blockchain-enabled smart contracts remains in full force and effect under the terms of the agreement dated November 24, 2025.
DataMEDS identifies its shares as trading on Nasdaq under the ticker NASDAQ:MEDS.
DataMEDS is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms. It incorporates the EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health.
EinsteinRx is DataMEDS's artificial intelligence platform, while PharmacyChain is its blockchain-enabled smart contracts platform. The company says both platforms are incorporated into the Health Lives Here mobile application from Tollo Health.
DataMEDS's pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health.
DataMEDS owns Helomics Corporation, a commercial clinical molecular diagnostics laboratory based in Pittsburgh, Pennsylvania. Helomics is focused on the ChemoFx Assay chemotherapy selection diagnostics test, which the company says aims to help oncologists make chemotherapy treatment decisions.
DataMEDS identifies risks including the effects of the LOI cancellation on its business, strategy and technology plans; its ability to complete alternative acquisitions, licences or partnerships; potential costs, claims or disputes; future securities issuances; execution of existing business plans; compliance with Nasdaq listing standards; and liquidity, capital resources and funding for operations. The company says actual results may differ materially from its forward-looking statements and that it undertakes no obligation to update them except as required by law.